A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

The NOTCH1gene encodes a ligand-activated transcription factor and is affected by stabilizing mutations in 10% CLL at diagnosis, 20% chemorefractory CLL and 30% of cases of Richter syndrome.

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.

BRUIN CLL-321 serves as the confirmatory trial to ... with 54% harboring 17p deletions and/or TP53 mutations, and over 60% with complex karyotype. They had been heavily pretreated as well, with ...

The advent of targeted therapies against FLT3 and IDH1/2 mutations underscores the clinical impact of molecular profiling. Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL ...